| Autor: |
Huisman, J. F., van Westreenen, H. L., van der Wouden, E. J., Vasen, H. F. A., de Graaf, E. J. R., Doornebosch, P. G., Tang, T. J., Schot, I., Brohet, R. M., de Vos tot Nederveen Cappel, W. H., Vermaas, M. |
| Předmět: |
|
| Zdroj: |
Techniques in Coloproctology; Jun2019, Vol. 23 Issue 6, p551-557, 7p |
| Abstrakt: |
Background: Anastomotic leak after rectal surgery is reported in 9% (range 3–28%) of patients. The aim of our study was to evaluate the effectiveness of endosponge therapy for anastomotic. Endpoints were the rate of restored continuity and the functional bowel outcome after anastomotic leakage. Methods: This was a multicenter retrospective observational cohort study. All patients with symptomatic anastomotic leakage after rectal surgery who had endosponge therapy between January 2012 and August 2017 were included. Functional bowel outcome was measured using the low anterior resection syndrome (LARS) score system. Results: Twenty patients were included. Eighteen patients had low anterior resection (90%) for rectal cancer. A diverting ileostomy was performed at primary surgical intervention in 14 patients (70%). Fourteen patients (70%) were treated with neoadjuvant (chemo-)radiotherapy. The median time between primary surgical intervention and first endosponge placement was 21 (5–537) days. The median number of endosponge changes was 9 (2–28). The success rate of the endosponge treatment was 88% and the restored gastrointestinal continuity rate was 73%. A chronic sinus occurred in three patients (15%). All patients developed LARS, of which 77% reported major LARS. Conclusions: Endosponge therapy is an effective treatment for the closure of presacral cavities with high success rate and leading to restored gastrointestinal continuity in 73%. However, despite endosponge therapy many patients develop major LARS. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink